☆ 3.8 Meeting Abstract

Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer

EJC SUPPLEMENTS (2008)

期刊

EJC SUPPLEMENTS

卷 6, 期 12, 页码 64-64

出版社

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/S1359-6349(08)72135-9

关键词

类别

Oncology

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

3.8

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo

Meng-di Dai, Yue-liang Wang, Jun Fan, Yang Dai, Yin-chun Ji, Yi-ming Sun, Xia Peng, Lan-lan Li, Yu-ming Wang, Wen-hu Duan, Jian Ding, Jing Ai

Summary: DW14383 is a promising selective irreversible pan-FGFR inhibitor with pan-tumor spectrum potential in FGFR1-4 aberrant cancers, which has the potential to overcome compensatory activation among FGFR1-4.

ACTA PHARMACOLOGICA SINICA (2021)

添加到收藏夹

Article Oncology

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital

Niamh Cunningham, Scott Shepherd, Kabir Mohammed, Karla A. Lee, Mark Allen, Stephen Johnston, Emma Kipps, Sophie McGrath, Jillian Noble, Marina Parton, Alistair Ring, Nicholas C. Turner, Alicia F. C. Okines

Summary: This study describes the tolerability and efficacy of neratinib as a monotherapy and in combination with capecitabine in advanced HER2-positive breast cancer. The results showed that neratinib was effective in both patients with and without brain metastases, with similar progression-free survival and overall survival rates as previous trials. Diarrhea was the most common adverse event but could be managed with prophylaxis. Routine anti-diarrheal prophylaxis allows this combination therapy to be safely delivered to patients in a real-world setting.

BREAST CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Oncology

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Gee-Chen Chang

Summary: This study aimed to investigate the efficacy of different EGFR-TKIs plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. The results showed that both erlotinib plus bevacizumab and afatinib plus bevacizumab as first-line treatment provided solid clinical efficacy in advanced EGFR-mutant lung adenocarcinoma patients.

CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK)

Tiancheng Fu, Yingying Zuo, Zhenpeng Zhong, Xuan Chen, Zhengying Pan

Summary: In this study, a novel series of selective and irreversible inhibitors of BLK were discovered, showing potent antiproliferative activities against several B-cell lymphoma cell lines. These compounds represent the first selective inhibitors developed for BLK, which could expedite the exploration of BLK functions.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Oncology

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

Sarina A. Piha-Paul, Chieh Tseng, Hai T. Tran, Meng Gao, Daniel D. Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D. Kawedia, Siqing Fu, Shubham Pant, Timothy A. Yap, Van K. Morris, Bryan K. Kee, Mariela Blum Murphy, JoAnn Lim, Funda Meric-Bernstam

Summary: The study aimed to evaluate the feasibility and safety of neratinib and trametinib combination therapy in patients with specific mutations/amplifications. The results showed that this combination therapy was toxic and had limited clinical efficacy, possibly due to suboptimal drug dosing caused by drug-drug interactions.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and Optimization of a Novel 2H-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor

Yujiao Wei, Yanting Tang, Yunyun Zhou, Yuyu Yang, Yetong Cui, Xuan Wang, Yubo Wang, Yulin Liu, Ning Liu, Qianqian Wang, Chong Li, Hao Ruan, Honggang Zhou, Mingming Wei, Guang Yang, Cheng Yang

Summary: The study identified a novel lead compound 36 with significant inhibitory effects against FGFR (1-3) and demonstrated low toxicity and adequate pharmacokinetic properties. Compound 36 also showed significant anti-proliferation effects against cancer cell lines NCI-H1581 and SNU-16, making it a potential drug candidate under validation.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno

Summary: This study identified everolimus and trametinib as potential inhibitors that enhance the anti-tumor activity of neratinib in HER2+ breast cancer and TNBC. The combination therapies significantly inhibited tumor growth in xenograft models and activated apoptosis pathway by reducing Ki67 expression.

BIOMEDICINES (2021)

添加到收藏夹

Article Endocrinology & Metabolism

EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas

Odelia Cooper, Vivien S. Bonert, Jeremy Rudnick, Barry D. Pressman, Janet Lo, Roberto Salvatori, Kevin C. J. Yuen, Maria Fleseriu, Shlomo Melmed

Summary: This study evaluated the effect of lapatinib, a tyrosine kinase inhibitor, on aggressive prolactinomas that are resistant to dopamine agonist therapy. While none of the participants achieved the primary endpoint, three showed stable disease and lapatinib was generally well tolerated with reversible side effects.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Medicine, General & Internal

Delta Radiomics Model Predicts Lesion-Level Responses to Tyrosine Kinase Inhibitors in Patients with Advanced Renal Cell Carcinoma: A Preliminary Result

Yuntian Chen, Enyu Yuan, Guangxi Sun, Bin Song, Jin Yao

Summary: This study aimed to develop and validate radiomic models based on computed tomography (CT) to predict the short-term response to tyrosine kinase inhibitors (TKIs) in patients with advanced renal cell carcinoma (RCC). The models showed promising discrimination capability and were well calibrated, suggesting their potential usefulness in guiding treatment decisions.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors

Shihe Hu, Yu Liu, Jiye Ma, Weijie Ding, Hua Chen, Haifang Jiang, Hongxing Chen, Song Wei, Yonggao Liu, Qiaomei Jin, Haoliang Yuan, Libo Yan

Summary: Under the guidance of molecular docking, we discovered a series of novel quinolone-based covalent pan-FGFR inhibitors, with the representative inhibitor I-5 exhibiting nanomolar activity against FGFR1-4 and effectively suppressing the proliferation of Huh-7 and Hep3B liver cells.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer

Zihong Wu, Jiamei Wang, Fengming You, Xueke Li, Chong Xiao

Summary: HER2-positive metastatic breast cancer is the leading cause of cancer death in women, and there is currently no optimal line of therapy after multiple treatment failures. Clinical trials have shown that treatment with irreversible pan-HER tyrosine kinase inhibitors in combination with chemotherapy significantly improves survival outcomes. Available findings suggest that irreversible pan-HER tyrosine kinase inhibitors, such as pyrotinib and neratinib, in combination with chemotherapy, may represent a beneficial salvage therapy for patients with HER2-positive metastatic breast cancer.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma

Shou-Wu Lee, Sheng-Shun Yang, Han-Chung Lien, Yen-Chun Peng, Chun-Fang Tung, Teng-Yu Lee

Summary: The study aimed to evaluate the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) as first-line therapy for advanced-stage hepatocellular carcinoma (HCC) patients. The results showed that this combination treatment provides acceptable antitumor efficacy, and there were no differences in survival outcomes between different drug combinations.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Oncology

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib

Stephanie N. Shishido, Rahul Masson, Liya Xu, Lisa Welter, Rishvanth Kaliappan Prabakar, Anishka D'Souza, Darcy Spicer, Irene Kang, Priya Jayachandran, James Hicks, Janice Lu, Peter Kuhn

Summary: Metastatic breast cancer (mBC) patients have a high risk of progression and poor prognosis. Liquid biopsy, particularly the analysis of cell-free DNA (cfDNA) and single circulating tumor cells (CTCs), can provide valuable clinical information for ERBB2 mutant, non-amplified mBC patients, guiding personalized oncology.

NPJ BREAST CANCER (2022)

添加到收藏夹

Article Oncology

Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours Long-term follow-up of nilotinib in TGCT

Geert Spierenburg, Peter Grimison, Christine Chevreau, Silvia Stacchiotti, Sophie Piperno-Neumann, Axel Le Cesne, Virginia Ferraresi, Antoine Italiano, Florence Duffaud, Nicolas Penel, Severine Metzger, Sylvie Chabaud, Lizz van der Heijden, David Perol, Michiel A. J. van de Sande, Jean-Yves Blay, Hans Gelderblom

Summary: Long-term analysis of nilotinib for advanced D-TGCT showed approximately half of patients experienced progression and required additional treatment after 8.5 years, while some patients maintained disease control after limited treatment duration.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Review Chemistry, Medicinal

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Giovanna Chila, Vincenzo Guarini, Danilo Galizia, Elena Geuna, Filippo Montemurro

Summary: Neratinib is a valuable therapeutic option for metastatic, HER2-positive breast cancer, particularly in cases of trastuzumab-resistant disease. Although it has shown positive effects on progression-free survival and response duration, it did not confer an overall survival benefit or improvement in quality of life in the NALA trial.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

添加到收藏夹

Review Oncology

Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer

Arsela Prelaj, Rebecca Tay, Roberto Ferrara, Nathalie Chaput, Benjamin Besse, Raffaele Califano

EUROPEAN JOURNAL OF CANCER (2019)

添加到收藏夹

Letter Oncology

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer Reply

Roberto Ferrara, Caroline Caramella, Benjamin Besse

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?

Arnaud Bayle, Benjamin Besse, Maxime Annereau, Julia Bonastre

EUROPEAN JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

Roberto Salgado, David B. Solit, David L. Rimm, Jan Bogaerts, Renzo Canetta, Tracy Lively, Kim Lyerly, Paul N. Span, Alison Bateman-House, Amr Makady, L. Bergmann, Sumimasa Nagai, Chris Smith, Mark Robson, Mary Savage, Emile Voest, Christopher Sweeney, Philippe Lambin, Marlene Thomas, Lyndsay Harris, Denis Lacombe, Chistophe Massard, Herbert K. Lyerly, Laura Yee, David Rimm, Alison Bateman-Houseaj, Lothar Bergmann, Sumimasa Nagaiam, Marlene Thomasan, Ian A. Cree, Shirley Hopper, Marc Robson, Magnus Ingelman-Sundberg, Francois Maignen, Benjamin Besse, Rafal Swierzewski, Astrid Kiermaier, Denis Lacombex, Tracy Livelyad, Christophe Massard, Roberto Salgadobf, Vassilis Golfinopoulos

EUROPEAN JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

Paul M. Putora, Markus Glatzer, Jose Belderbos, Benjamin Besse, Fiona Blackhall, Raffaele Califano, Federico Cappuzzo, Filippo de Marinis, Rafal Dziadziuszko, Enriqueta Felip, Corinne Faivre-Finn, Martin Fruh, Pilar Garrido, Cecila Le Pechoux, Fiona McDonald, Ursula Nestle, Silvia Novello, Mary O'Brien, Luis Paz Ares, Stephanie Peeters, Christoph Pottgen, Sara Ramella, Martin Reck, Ben Slotman, Esther G. C. Troost, Paul Van Houtte, Virginie Westeel, Joachim Widder, Francoise Mornex, Dirk De Ruysscher

RADIOTHERAPY AND ONCOLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

Immune-related pneumonitis in NSCLC patients treated with ICI: impact of previous thoracic RT

A. Botticella, T. Ibrahim, L. Mezquita, L. Hendriks, J. Le Pavec, R. Ferrara, C. Caramella, S. Champiat, J. Michot, P. Lavaud, P. Gustin, D. Planchard, A. Gazzah, A. Marabelle, E. Deutsch, B. Besse, C. Le Pechoux

RADIOTHERAPY AND ONCOLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey

A. Levy, L. E. L. Hendriks, C. Le Pechoux, S. Falk, B. Besse, S. Novello, A. C. Dingemans, B. Hasan, M. Reck, T. Berghmans, C. Faivre-Finn

RADIOTHERAPY AND ONCOLOGY (2019)

添加到收藏夹

Editorial Material Critical Care Medicine

Exploring the optimal use of alectinib

Diego Enrico, Christophe Massard, Benjamin Besse

LANCET RESPIRATORY MEDICINE (2019)

添加到收藏夹

Editorial Material Oncology

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Jordi Remon, Noemi Reguart, Edouard Auclin, Benjamin Besse

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Editorial Material Oncology

Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer

Jordi Remon, Lizza E. L. Hendriks, Benjamin Besse

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials

Julie Delorme, Valentin Charvet, Muriel Wartelle, Francois Lion, Bruno Thuillier, Sandrine Mercier, Jean-Charles Soria, Mikael Azoulay, Benjamin Besse, Christophe Massard, Antoine Hollebecque, Loic Verlingue

Summary: The study aimed to predict successful completion of screening and dose-limiting toxicity period in early-phase oncology trials using machine learning. By transforming consultation reports into semantic vectors and clustering them, a model was trained to achieve high performance in predicting patient outcomes.

JCO CLINICAL CANCER INFORMATICS (2021)

添加到收藏夹

Article Oncology

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M. Gadgeel, D. Ross Camidge, Anthonie J. van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S. Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R. Soglia, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola Zhu, Monika A. Davare, Aaron N. Hata, Henry E. Pelish, Jessica J. Lin

CANCER DISCOVERY (2023)

添加到收藏夹

Editorial Material Oncology

Does perioperative immunotherapy reduce the risk of second primary cancers?

Marco Tagliamento, Jordi Remon, David Planchard, Benjamin Besse

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Meeting Abstract Oncology

Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials

A. Varga, A. Bernard-Tessier, E. Auclin, L. Mezquita Perez, C. Baldini, D. Planchard, A. Marabelle, A. Hollebecque, B. Besse, C. Massard

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer

Jordi Remon, Ludovic Lacroix, Cecile Jovelet, Caroline Caramella, Karen Howarth, Vincent Plagnol, Nitzan Rosenfeld, Clive Morris, Laura Mezquita, Chloe Pannet, Maud Ngocamus, Cecile Le Pechoux, Julien Adam, Alina-Miruna Grecea, David Planchard, Gilles Vassal, Jose Carlos Benitez, Anas Gazzah, Emma Green, Jean-Charles Soria, Benjamin Besse

JCO PRECISION ONCOLOGY (2019)

添加到收藏夹

暂无数据

Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer

期刊

出版社

PERGAMON-ELSEVIER SCIENCE LTD

关键词

类别

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

评论

主要评分

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

推荐

导出引文

分享论文